PDF herunterladen
Nervenheilkunde 2020; 39(09): 559-564
DOI: 10.1055/a-1213-7110
Schwerpunkt
© Georg Thieme Verlag KG Stuttgart · New York

The impact of gender on the progression of neuromanifestation in HIV infection

A case-control studyDer Einfluss des Geschlechts auf die Entwicklung der Neuromanifestation bei einer HIV-InfektionEine Fall-Kontroll-Studie
Stefan Evers
1   Department of Neurology, Lindenbrunn Hospital, Copppenbrügge
,
Esra Akova-Öztürk∗
2   Department of Neurology, University of Münster
,
Altynchach Moldokmatova∗
2   Department of Neurology, University of Münster
,
Doris Reichelt∗
3   Department of Medicine D, University of Münster
,
Nora Gregor∗
2   Department of Neurology, University of Münster
,
Ingo W. Husstedt∗
2   Department of Neurology, University of Münster
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
24. August 2020 (online)

    Lizenzen und Reprints

ZUSAMMENFASSUNG

Ds Geschlecht hat einen besonderen Einfluss auf den Verlauf, die Manifestationen und die Behandlung einer HIV-Infektion. Es ist aber nur wenig bekannt über den spezifischen Einfluss des Geschlechts auf die Neuromanifestation. Wir wollten daher Unterschiede in der Prävalenz und in dem Grad der Neuromanifestationen zwischen Frauen und Männern mit HIV-Infektionen evaluieren und haben deshalb eine Fall-Kontroll-Studie mit konsekutiven HIV-infizierten Frauen (n = 167) and Männern (n = 169) durchgeführt, die für die Dauer der Infektion gematcht waren. Die Studie wurde an einer überregionalen HIV-Ambulanz einer neurologischen und an einer medizinischen Klinik durchgeführt. Es wurden die demografischen, klinischen, neurologischen, neurophysiologischen (ereigniskorrelierte Potenziale, Neurografie) und Bildgebungsdaten verglichen. Frauen waren zum Zeitpunkt der Infektion signifikant jünger als Männer. Sie zeigten weniger fortgeschrittene Stadien der HIV-Infektion und eine höhere CD4+-Zellzahl. Frauen erhielten seltener eine antiretrovirale Therapie. Die Nervenleitgeschwindigkeiten und Latenzen der ereigniskorrelierten Potenziale waren signifikant besser bei Frauen. Sie hatten eine signifikant niedrigere Rate einer Polyneuropathie und von generalisierten opportunistischen Infektionen. Außerdem zeigte sich ein Trend zu einer geringeren Rate einer HIV-assoziierten Enzephalopathie bei Frauen. Zusammenfassend zeigten Frauen einen besseren immunologischen Status und eine geringere Rate von Neuromanifestationen im Vergleich zu Männern mit derselben Infektionsdauer.

ABSTRACT

Gender has a considerable impact on the course, the manifestations, and the treatment of HIV infection. However, only little is known on the specific impact on neuromanifestation of HIV infection. We tried to investigate differences in the prevalence and severity of neuromanifestations between female and male HIV-infected patients and designed a case-control study with consecutive HIV-infected women (n = 167) and HIV-infected men (n = 169) matched for duration of infection. The study was performed in a supraregional HIV outpatient clinic of a neurological and of a medical university department. It included the review of demographic, clinical, neurological, neurophysiological (event-related potentials, neurography), and brain imaging data. Women were significantly younger at the time of infection. They showed less severe stages of the HIV infection and higher CD4 + cell counts. However, they were significantly more often under no antiretroviral therapy. Nerve conduction and latencies of event-related potentials were found to be significantly better in women. There were significantly lower rates of polyneuropathy and of generalized opportunistic infections and a trend to a lower rate of HIV-associated neurocognitive disorders in women. In summary, women exhibit a better immunological state and a lower rate of neuromanifestations as compared to men with the same duration of infection.

Schlüsselwörter

Geschlecht - Neuromanifestation - HIV-Infektion - AIDS

Key words

Gender - neuromanifestation - HIV infection - AIDS
 

  • References

  • 1 The United Nations Joint Programme of HIV/AIDS (UNAID). AIDS epidemic update 2007. Geneva: UNAIDS; 2007
  • 2 Kelly JA, Amirkhanian YA. The newest epidemic: a review of HIV/AIDS in central and eastern europe.. Int J STD AIDS 2003; 14: 361-371
    CrossrefPubMedGoogle Scholar
  • 3 Farzadegan H, Hoover DR, Astemborski J. et al Sex differences in HIV-1 viral load and progression to AIDS.. Lancet 1998; 352: 1510-1514
    CrossrefPubMedGoogle Scholar
  • 4 Sterling TR, Lyles CM, Vlahov D. et al Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters.. J Infect Dis 1999; 180: 666-672
    CrossrefPubMedGoogle Scholar
  • 5 Moroni M. Sex differences in HIV-1 viral load and progression to AIDS. ICONA Study Group. Italian Cohort of HIV-1 positive individuals.. Lancet 1999; 353: 589-590
    CrossrefPubMedGoogle Scholar
  • 6 Napravnik S, Poole C, Thomas JC. et al Gender difference in HIV RNA levels: a meta-analysis of published studies.. J Acquir Immune Defic Syndr 2002; 31: 11-19
    CrossrefPubMedGoogle Scholar
  • 7 Kremer H, Sonnenberg-Schwan U. Women living with HIV. Does sex and gender matter? A current literature review.. Eur J Med Res 2003; 8: 8-16
    PubMedGoogle Scholar
  • 8 Armbruster C, Kriwanek S, Vorbach H. Gender-specific differences in the natural history, clinical features, and socioeconomic status of HIV-infected patients: experience of a treatment centre in Vienna.. Wien Klin Wochenschr 2000; 112: 754-760
    PubMedGoogle Scholar
  • 9 Gilad J, Walfisch A, Borer A. et al Gender differences and sex-specific manifestations associated with human immunodeficiency virus infection in women.. Eur J Obstet Gynecol Reprod Biol 2003; 109: 199-205
    CrossrefPubMedGoogle Scholar
  • 10 Spijkermann IJB, Langendam MW, van Ameijden EJC. et al Gender differences in clinical manifestations before AIDS diagnosis among injecting drug users.. Eur J Epidemiol 1998; 14: 213-218
    CrossrefPubMedGoogle Scholar
  • 11 Kaplan JE, Hanson D, Dworkin MS. et al Epidemiology of human immunodeficiency virus-associated opportunistic infections in the united states in the era of highly active antiretroviral therapy.. Clin Infect Dis 2000; 30: 5-14
    CrossrefPubMedGoogle Scholar
  • 12 Phillips AN, Antunes F, Stergious G. et al A sex comparison of rates of new AIDS-defining disease and death in 2554 AIDS cases. AIDS in Europe Study Group.. AIDS 1994; 8: 831-835
    CrossrefPubMedGoogle Scholar
  • 13 Shiboski CH, Hilton JF, Neuhaus JM. et al Human immunodeficiency virus-related oral manifestations and gender.. Arch Intern Med 1996; 156: 2249-2254
    CrossrefPubMedGoogle Scholar
  • 14 Robertson K, Vaughn B, Kapoor C. et al Gender and neurological functioning in HIV-infection. 7th Conference on Retroviruses and Opportunistic Infections, Foundation for Retrovirology and Human Health. 2000
    PubMedGoogle Scholar
  • 15 Lopez OL, Wess J, Sanchez J. et al Neurological characteristics of HIV-infected men and women seeking primary medical care.. Eur J Neurol 1999; 6: 205-209
    CrossrefPubMedGoogle Scholar
  • 16 Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs.. Top HIV Med 2003; 11: 55-59
    PubMedGoogle Scholar
  • 17 Adams J, Frost C, Shelton M. Indinavir pharmacokinetics and menstrual cycle physiology. In: Proceedings of the Fifth Conference on Retroviruses and Opportunistic Infections.. Chicago (IL): Foundation for Retrovirology and Human Health; 1998. Abstract no. 356
    Google Scholar
  • 18 Moore AL, Kirk O, Johnson AM. et al Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited.. J Acquir Immune Defic Syndr 2003; 32: 452-461
    CrossrefPubMedGoogle Scholar
  • 19 Centers for Disease Control. 1993 revised classification system for HIV infection.. MMWR 1992; 41: 1-19
    PubMedGoogle Scholar
  • 20 Husstedt IW, Evers S, Reichelt D. et al Screening for HIV-associated distal-symmetric polyneuropathy in CDC-classification stages 1, 2, and 3.. Acta Neurol Scand 2000; 101: 183-187
    CrossrefPubMedGoogle Scholar
  • 21 Evers S, Rahmann A, Schwaag S. et al Prevention of AIDS dementia by HAART does not depend on cerebrospinal fluid drug penetrance.. AIDS Res Hum Retroviruses 2004; 20: 483-491
    CrossrefPubMedGoogle Scholar
  • 22 Kalish LA, Collier AC, Flanigan TP. et al Plasma human immunodeficiency virus (HIV) type 1 RNA load in men and women with advanced HIV-1 disease.. J Infect Dis 2000; 182: 603-606
    CrossrefPubMedGoogle Scholar
  • 23 Levine A. Evaluation and management of HIV-infected women.. Ann Intern Med 2002; 136: 228-242
    CrossrefPubMedGoogle Scholar
  • 24 The Italian Seroconversion Study. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users.. AIDS 1992; 6: 421-426
    CrossrefPubMedGoogle Scholar
  • 25 Morgello S, Mahboob R, Yakoushina T. et al Autopsy findings in a human immunodeficiency virus-infected population over 2 decades.. Arch Pathol Lab Med 2002; 126: 182-190
    CrossrefPubMedGoogle Scholar
  • 26 Prins M, Robertson JR, Brettle RP. et al Do gender differences in CD4 cell counts matter?. AIDS 1999; 13: 2361-2364
    CrossrefPubMedGoogle Scholar
  • 27 Greenblatt RM, Ameli N, Grant RM. et al Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women.. JID 2000; 181: 82-90
    CrossrefPubMedGoogle Scholar
  • 28 Lee A, Mitra D, Laurence J. Interaction of pregnancy steroid hormones and zidovudine in inhibition of HIV type 1 replication in monocytoid and placental Hofbauer cells: implications for the prevention of maternal-fetal transmission of HIV.. AIDS Res Hum Retroviruses 1997; 13: 1235-1242
    CrossrefPubMedGoogle Scholar
  • 29 van Benthem BHB, Vernazza P, Coutinho RA. et al The impact of pregnancy and menopause on CD4 lymphocyte counts in HIV-infected women.. AIDS 2002; 16: 919-924
    CrossrefPubMedGoogle Scholar
  • 30 Howard AA, Arnsten JH, Yungtai L. et al A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women.. AIDS 2002; 16: 2175-2182
    CrossrefPubMedGoogle Scholar
  • 31 Kempf MC, Pisu M, Dumcheva A. et al Gender differences in discontinuation of antiretroviral treatment regimens.. J Acquir Immune Defic Syndr 2009; 52: 336-341
    CrossrefPubMedGoogle Scholar
  • 32 Kremer H, Sonnenberg-Schwan U. et al HIV or HIV-therapy? Causal attributions of symptoms and their impact on treatment decisions among women and men with HIV.. Eur J Med Res 2009; 14: 139-146
    CrossrefPubMedGoogle Scholar
  • 33 Bersoff-Matcha SJ, Miller WC, Aberg JA. et al Sex differences in nevirapine rash.. CID 2001; 32: 124-129
    CrossrefPubMedGoogle Scholar
  • 34 Robinson LR, Rubner DE, Wahl PW. et al Influences of height and gender on normal nerve conduction studies.. Arch Phys Med Rehabil 1993; 74: 1134-1138
    CrossrefPubMedGoogle Scholar
  • 35 Simpson DM, Haidich AB, Schifitto G. et al Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels.. AIDS 2002; 16: 407-412
    CrossrefPubMedGoogle Scholar
  • 36 Robertson KR, Kapoor C, Robertson WT. et al No gender differences in the progression of nervous system disease in HIV infection.. J Acquir Immune Defic Syndr 2004; 36: 817-822
    CrossrefPubMedGoogle Scholar
  • 37 Carvour ML, Harms JP, Lynch CF. et al Differential Survival for Men and Women with HIV/AIDS-Related Neurologic Diagnoses.. PLoS One 2015; 10: e0123119
    CrossrefPubMedGoogle Scholar
  • 38 Coelho L, Grinsztejn B, Castilho JL. et al Mortality in HIV-infected women, heterosexual men, and men who have sex with men in Rio de Janeiro, Brazil: an observational cohort study.. Lancet HIV 2016; 3: e490-e498
    CrossrefPubMedGoogle Scholar
  • 39 Shelton PP, Hartmann AM, Allen J. Seasonal photoperiod, gender, and P300.. Biol Psychol 2002; 60: 151-171
    CrossrefPubMedGoogle Scholar
  • 40 Kudo N, Nakagome K, Kasai K. et al Effects of corollary discharge on event-related potentials during selective attention task in healthy men and women.. Neurosci Res 2004; 48: 59-64
    CrossrefPubMedGoogle Scholar
  • 41 Eggers CH. German Neuro-AIDS Working Group. HIV-1 associated encephalopathy and myelopathy.. J Neurol 2002; 249: 1132-1136
    CrossrefPubMedGoogle Scholar
  • 42 Rezza G, Dorrucci M, Andreoni M. et al Does HHV-8 have a protective role on the development of HIV encephalopathy? Italian HIV-Seroconversion Study.. Neurology 1999; 53: 2032-2036
    CrossrefPubMedGoogle Scholar